Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.

Bingen E, Bidet P, Birgy A, Sobral E, Mariani P, Cohen R.

J Clin Microbiol. 2012 Jul;50(7):2540-1. doi: 10.1128/JCM.00526-12. No abstract available.

2.
3.

Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.

Livermore DM, Hope R, Mushtaq S, Warner M.

Clin Microbiol Infect. 2008 Jan;14 Suppl 1:189-93. Review. Erratum in: Clin Microbiol Infect. 2008 May;14 Suppl 5:21-4.

4.

Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.

Stürenburg E, Sobottka I, Noor D, Laufs R, Mack D.

J Antimicrob Chemother. 2004 Jul;54(1):134-8.

5.

Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.

Drieux L, Brossier F, Sougakoff W, Jarlier V.

Clin Microbiol Infect. 2008 Jan;14 Suppl 1:90-103. Review. Erratum in: Clin Microbiol Infect. 2008 May;14 Suppl 5:21-4.

6.
7.
8.

Occurrence of extended-spectrum beta-lactamases in Enterobacteriaceae isolated from hospitalized patients in Curitiba, southern Brazil.

Nogueira Kda S, Higuti IH, do Nascimento AJ, Terasawa LB, de Oliveira S, Matos AP, de Souza HA, Cogo LL, Dalla Costa LM.

Braz J Infect Dis. 2006 Dec;10(6):390-5.

9.
10.
11.
12.

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM.

J Antimicrob Chemother. 2007 Aug;60(2):300-11.

13.

Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G; Italian ESBL Study Group..

Antimicrob Agents Chemother. 2002 Jan;46(1):196-202.

14.

Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.

Prakash V, Lewis JS 2nd, Herrera ML, Wickes BL, Jorgensen JH.

Antimicrob Agents Chemother. 2009 Mar;53(3):1278-80. doi: 10.1128/AAC.01519-08.

15.

[Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].

Philippon A, Jarlier V, Legrand P, Fournier G, Nicolas MH, Duval J.

Presse Med. 1989 Oct 11;18(32):1560-6. French.

PMID:
2530532
16.

Extended-spectrum-beta-lactamase-producing Enterobacteriaceae in Yaounde, Cameroon.

Gangoué-Piéboji J, Bedenic B, Koulla-Shiro S, Randegger C, Adiogo D, Ngassam P, Ndumbe P, Hächler H.

J Clin Microbiol. 2005 Jul;43(7):3273-7.

17.

Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.

Tajada P, Gomez-Graces JL, Alós JI, Balas D, Cogollos R.

Antimicrob Agents Chemother. 1996 Aug;40(8):1924-5.

18.
19.

In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.

Chin NX, Gu JW, Neu HC.

Eur J Clin Microbiol Infect Dis. 1990 Sep;9(9):685-91.

PMID:
2226499
20.

Extended-spectrum beta-lactamases: a clinical update.

Paterson DL, Bonomo RA.

Clin Microbiol Rev. 2005 Oct;18(4):657-86. Review.

Items per page

Supplemental Content

Support Center